Lonza 
Welcome,         Profile    Billing    Logout  
 5 Products   14 Diseases  5 Products   6 Trials   195 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
deramiocel (CAP-1002) / Capricor, Lonza, Nippon Shinyaku
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
HOPE-OLE, NCT06304064: Halt cardiomyOPathy progrEssion in Duchenne

Completed
2
8
US
Allogeneic Cardiosphere-Derived Cells (CAP-1002), CAP-1002
Capricor Inc.
Duchenne Muscular Dystrophy
03/19
03/19
HOPE-2-OLE, NCT04428476: Open-label Extension of the HOPE-2 Trial

Active, not recruiting
2
13
US
Deramiocel (CAP-1002), Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
Duchenne Muscular Dystrophy
02/22
03/26
Regress-HFpEF, NCT02941705: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

Completed
2
27
US
Allogeneic Derived Cells, CAP-1002, Placebo/Control Arm, Placebo
Cedars-Sinai Medical Center, Medical University of South Carolina
Congestive Heart Failure, Heart Failure, Diastolic
04/23
05/23
NCT01815060: Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells

Not yet recruiting
1/2
314
US
CAP-1002 Allogeneic Cardiosphere-Derived Cells, placebo, same formulation as the experimental infusion except without the cardiosphere-derived cells (CDCs)
Eduardo Marban, MD, PhD
Dilated Cardiomyopathy (DCM)
08/14
07/15
ALPHA, NCT03145298: ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Completed
1
26
US
Allogeneic Human Cardiosphere-Derived Stem Cells, CAP-1002, Placebo
Cedars-Sinai Medical Center, California Institute for Regenerative Medicine (CIRM)
Pulmonary Arterial Hypertension (PAH)
01/23
03/23
NCT04338347: CAP-1002 in Severe COVID-19 Disease

No Longer Available
N/A
US
CAP-1002 Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
COVID-19
 
 
abelacimab (MAA868) / Novartis
ASTER, NCT05171049 / 2021-003076-14: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Recruiting
3
1655
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Apixaban, Eliquis
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
12/26
02/27
MAGNOLIA, NCT05171075 / 2021-003085-12: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Recruiting
3
1020
Europe, Canada, US, RoW
Abelacimab, MAA868, Dalteparin, Fragmin
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
12/26
02/27
LILAC-TIMI 76, NCT05712200: Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation

Recruiting
3
1900
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Placebo
Anthos Therapeutics, Inc.
Atrial Fibrillation (AF)
08/26
10/26
2019-003756-37: A study to compare study drug MAA868 with standard of care (enoxaparin) in adults undergoing knee surgery

Ongoing
2
600
Europe, RoW
Abelacimab, Enoxaparin, MAA868, Concentrate for solution for infusion, Solution for injection in pre-filled syringe, Clexane
Anthos Therapeutics, Anthos Therapeutics
Elective unilateral total knee arthroplasty, Knee surgery, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
2020-004507-13: A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate.

Not yet recruiting
2
1200
Europe, RoW
Abelacimab, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets, MAA868, Concentrate for solution for injection, Film-coated tablet, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets
Anthos Therapeutics, Anthos Therapeutics
Atrial Fibrillation, A heart condition that causes an irregular and abnormally fast heart rate., Diseases [C] - Cardiovascular Diseases [C14]
 
 
AZALEA-TIMI 71, NCT04755283 / 2020-004507-13: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Hourglass Jan 2023 - Jun 2023 : Safety and tolerability data from AZALEA-TIMI 71 trial in patients with atrial fibrillation
Active, not recruiting
2
1287
Europe, Canada, US, RoW
Abelacimab, MAA868, Rivaroxaban
Anthos Therapeutics, Inc., The TIMI Study Group, Fortrea
Atrial Fibrillation (AF), Stroke
02/24
12/25
TAC100-HER2 / Triumvira, Lonza
TACTIC-2, NCT04727151: TAC T-cells for the Treatment of HER2-positive Solid Tumors

Terminated
1/2
28
Canada, US
TAC01-HER2, TAC01-HER2 plus pembrolizumab, Keytruda
Triumvira Immunologics, Inc., Merck Sharp & Dohme LLC
HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
12/23
03/24
IMT-009 / Immunitas Therap, Lonza
NCT05565417: Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas

Recruiting
1/2
151
US
IMT-009, Fruquintinib, fruzaqla
Immunitas Therapeutics
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
04/25
04/25
MGC026 / MacroGenics
NCT06242470: A Study of MGC026 in Participants With Advanced Solid Tumors

Recruiting
1
250
Europe, US, RoW
MGC026 Dose Escalation, MGC026 Dose for Expansion
MacroGenics
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
05/28
10/28
Undisclosed ADC therapeutic / Eli Lilly, Lonza
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
deramiocel (CAP-1002) / Capricor, Lonza, Nippon Shinyaku
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
HOPE-OLE, NCT06304064: Halt cardiomyOPathy progrEssion in Duchenne

Completed
2
8
US
Allogeneic Cardiosphere-Derived Cells (CAP-1002), CAP-1002
Capricor Inc.
Duchenne Muscular Dystrophy
03/19
03/19
HOPE-2-OLE, NCT04428476: Open-label Extension of the HOPE-2 Trial

Active, not recruiting
2
13
US
Deramiocel (CAP-1002), Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
Duchenne Muscular Dystrophy
02/22
03/26
Regress-HFpEF, NCT02941705: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

Completed
2
27
US
Allogeneic Derived Cells, CAP-1002, Placebo/Control Arm, Placebo
Cedars-Sinai Medical Center, Medical University of South Carolina
Congestive Heart Failure, Heart Failure, Diastolic
04/23
05/23
NCT01815060: Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells

Not yet recruiting
1/2
314
US
CAP-1002 Allogeneic Cardiosphere-Derived Cells, placebo, same formulation as the experimental infusion except without the cardiosphere-derived cells (CDCs)
Eduardo Marban, MD, PhD
Dilated Cardiomyopathy (DCM)
08/14
07/15
ALPHA, NCT03145298: ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Completed
1
26
US
Allogeneic Human Cardiosphere-Derived Stem Cells, CAP-1002, Placebo
Cedars-Sinai Medical Center, California Institute for Regenerative Medicine (CIRM)
Pulmonary Arterial Hypertension (PAH)
01/23
03/23
NCT04338347: CAP-1002 in Severe COVID-19 Disease

No Longer Available
N/A
US
CAP-1002 Allogeneic Cardiosphere-Derived Cells
Capricor Inc.
COVID-19
 
 
abelacimab (MAA868) / Novartis
ASTER, NCT05171049 / 2021-003076-14: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Recruiting
3
1655
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Apixaban, Eliquis
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
12/26
02/27
MAGNOLIA, NCT05171075 / 2021-003085-12: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Recruiting
3
1020
Europe, Canada, US, RoW
Abelacimab, MAA868, Dalteparin, Fragmin
Anthos Therapeutics, Inc., Itreas
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
12/26
02/27
LILAC-TIMI 76, NCT05712200: Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation

Recruiting
3
1900
Europe, Canada, Japan, US, RoW
Abelacimab, MAA868, Placebo
Anthos Therapeutics, Inc.
Atrial Fibrillation (AF)
08/26
10/26
2019-003756-37: A study to compare study drug MAA868 with standard of care (enoxaparin) in adults undergoing knee surgery

Ongoing
2
600
Europe, RoW
Abelacimab, Enoxaparin, MAA868, Concentrate for solution for infusion, Solution for injection in pre-filled syringe, Clexane
Anthos Therapeutics, Anthos Therapeutics
Elective unilateral total knee arthroplasty, Knee surgery, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
2020-004507-13: A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is comapred to another drug called Rivaroxaban in patients with heart condition that causes an irregular and abnormally fast heart rate.

Not yet recruiting
2
1200
Europe, RoW
Abelacimab, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets, MAA868, Concentrate for solution for injection, Film-coated tablet, Xarelto 15mg film-coated tablets, Xarelto 20mg film-coated tablets
Anthos Therapeutics, Anthos Therapeutics
Atrial Fibrillation, A heart condition that causes an irregular and abnormally fast heart rate., Diseases [C] - Cardiovascular Diseases [C14]
 
 
AZALEA-TIMI 71, NCT04755283 / 2020-004507-13: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Hourglass Jan 2023 - Jun 2023 : Safety and tolerability data from AZALEA-TIMI 71 trial in patients with atrial fibrillation
Active, not recruiting
2
1287
Europe, Canada, US, RoW
Abelacimab, MAA868, Rivaroxaban
Anthos Therapeutics, Inc., The TIMI Study Group, Fortrea
Atrial Fibrillation (AF), Stroke
02/24
12/25
TAC100-HER2 / Triumvira, Lonza
TACTIC-2, NCT04727151: TAC T-cells for the Treatment of HER2-positive Solid Tumors

Terminated
1/2
28
Canada, US
TAC01-HER2, TAC01-HER2 plus pembrolizumab, Keytruda
Triumvira Immunologics, Inc., Merck Sharp & Dohme LLC
HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
12/23
03/24
IMT-009 / Immunitas Therap, Lonza
NCT05565417: Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas

Recruiting
1/2
151
US
IMT-009, Fruquintinib, fruzaqla
Immunitas Therapeutics
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
04/25
04/25
MGC026 / MacroGenics
NCT06242470: A Study of MGC026 in Participants With Advanced Solid Tumors

Recruiting
1
250
Europe, US, RoW
MGC026 Dose Escalation, MGC026 Dose for Expansion
MacroGenics
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
05/28
10/28
Undisclosed ADC therapeutic / Eli Lilly, Lonza
No trials found

Download Options